drugset

drugset / Trial / NCT02348905

ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial

NCT02348905 ↗

Phase 2/3 Unknown 10 enrolled Albany Medical College

RandomizedParallel-groupOpen-labelTreatment

Summary

ACTHAR gel has efficacy in the treatment of cutaneous sarcoidosis

Timeline

Start: 2015-03
Primary completion: 2015-07
Completion: 2016-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acthar	Peptide	40 iu	Subcutaneous
Subject	Acthar	Peptide	80 iu	Subcutaneous

Indications